Antibodies to synthetic peptides of the α1A subunit of the voltage- gated calcium channel in Lambert-Eaton myasthenic syndrome

Neurology

Volumn 48, Issue 5, 1997, Pages 1261-1265

  Takamori, Masaharu ^a   Iwasa, Kazuo ^a   Komai, Kiyonobu ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BRAIN EXTRACT; CALCIUM CHANNEL;

ANTIBODY DETECTION; ARTICLE; CEREBELLUM; CHANNEL GATING; CLINICAL ARTICLE; CONTROLLED STUDY; EATON LAMBERT SYNDROME; HUMAN; LUNG SMALL CELL CANCER; MYASTHENIA GRAVIS; PRIORITY JOURNAL;

EID: 0030988558     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.5.1261     Document Type: Article

References (31)

1. Vincent A, Lang B, Newsom-Davis J. Autoimmunity to the voltage-gated calcium channels underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci 1989;12:496-502.
2. Birnbaumer L, Campbell KP, Catterall WA, et al. The naming of voltage-gated calcium channels. Neuron 1994;13:505-506.
3. 2+ channels in mammalian central neurons. Trends Neurosci 1995;18:89-98.
4. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
5. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myastheníc syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-87.
6. Takamori M, Takahashi M, Yasukawa Y, et al. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J Neurol Sci 1995;133:95-101.
7. Stea A, Tomlinson WJ, Soong TW, et al. Localization and functional properties of a rat brain α1A calcium channel reflect similarities to neuronal Q- and P-type channels. Proc Natl Acad Sci USA 1994;91:10576-10580.
8. 2+ channel currents in rat cerebellar granule neurons. J Neurosci 1995;15:2995-3012.
9. 2+ channels: diversity of form and function. Curr Opin Neurobiol 1992;2:247-253.
10. 2+ channel diversity. Annu Rev Neurosci 1994;17:399-418.
11. O'Neill JH, Murray NMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577-596.
12. Mori Y, Friedrich T, Kim M-S, et al. Primary structure and functional expression from complementary DNA of a brain calcium channel. Nature 1991;350:398-402.
13. Merrifield RB. Automated synthesis of peptides. Solid-phase peptide synthesis, a simple and rapid synthesis method, has now been automated. Science 1965;150:178-185.
14. Barry ELR, Viglione MP, Kim YI, Froehner SC. Expression and antibody inhibition of P-type calcium channels in human small-cell lung carcinoma cells. J Neurosci 1995;15:274-283.
15. Starr TVB, Prystay W, Snutch TP. Primary structure of a calcium channel that is highly expressed in the rat cerebellum. Proc Natl Acad Sci USA 1991;88:5621-5625.
16. 2+ channels. Neuron 1992;9:69-77.
17. Llinás R, Sugimori M, Lin J-W, Cherksey B. Blocking and isolation of a calcium channel from neurons in mammals and cephalopods utilizing a toxin fraction (FTX) from funnel-web spider poison. Proc Natl Acad Sci USA 1989;86:1689-1693.
18. Uchitel OD, Protti DA, Sanchez V, Cherksey BD, Sugimori M, Llinás R. P-type voltage-dependent calcium channel mediates presynaptic calcium influx and transmitter release in mammalian synapses. Proc Natl Acad Sci USA 1992;89:3330-3333.
19. Protti DA, Reisin R, Mackinley TA, Uchitel OD. Calcium channel blockers and transmitter release at the normal human neuromuscular junction. Neurology 1996;46:1391-1396.
20. Kim YI, Longacher JM, Viglione MP. ω-Agatoxin IVA blocks evoked quantal transmitter release at the mammalian neuro-muscular junction [abstract]. Mol Biol Cell 1993;4:428.
21. Sugiura Y, Woppmann A, Miljanich GP, Ko C-P. A novel ω-conopeptide for the presynaptic localization of calcium channels at the mammalian neuromuscular junction. J Neurocytol 1995;24:15-27.
22. Ousley AH, Froehner SC. An anti-peptide antibody specific for the class A calcium channel α1 subunit labels mammalian neuromuscular junction. Proc Natl Acad Sci USA 1994;91:12263-12267.
23. Leys K, Lang B, Johnston I, Newsom-Davis J. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann Neurol 1991;29:307-314.
24. Sher E, Gotti C, Canal N, et al. Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet 1989;2:640-643.
25. Login IS, Kim YI, Judd AM, Spangelo BL, MacLeod RM. Immunoglobulins of Lambert-Eaton myasthenic syndrome inhibit rat pituitary hormone release. Ann Neurol 1987;22:610-614.
26. Oguro-Okano M, Griesmann GE, Wieben ED, Slaymaker SJ, Snutch TP, Lennon VA. Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc 1992;67:1150-1159.
27. David P, Far OE, Martin-Mouto N, Poupon MF, Takahashi M, Seagar MJ. Expression of synaptotagmin and syntaxin associated with N-type calcium channels in small cell lung cancer. FEBS Lett 1993;326:135-139.
28. Williams ME, Brust PF, Feldman DH, et al. Structure and functional expression of an ω-conotoxin-sensitive human N-type calcium channel. Science 1992;257:389-395.
29. Takamori M, Hamada T, Okumura S. Myasthenogenicity in the main immunogenic region of acetylcholine receptor as modified by conformational design: an approach to antigenic synthetic peptides. J Neurol Sci 1992;109:182-187.
30. Rose GD, Gierasch LM, Smith JA, Turns in peptides and proteins. Adv Protein Chem 1985;37:1-109.
31. Dyson HJ, Cross KJ, Houghten RA, Wilson IA, Wright PE, Lerner RA. The immunodominant site of a synthetic immunogen has a conformational preference in water for a type-II reverse turn. Nature 1985;318:480-483.